References
- Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163 (7): 1730–1754.
- Bartlett JG, Mundy LM. Community-acquired pneumo-nia. N Engl J Med 1997; 10: 1530–1534.
- Mandell LA. Update on community-acquired pneumonia. New pathogens and new concepts in treatment. Postgrad Med 2005; 118 (4): 35-36, 41-46.
- European Respiratory Society. Guidelines for the man-agement of adult lower respiratory tract infections. Eur Respir J 2005; 26 (6): 1138–1180.
- Afessa B, Green B. Bacterial pneumonia in hospitalised patients with HIV infection: the pulmonary complications, ICU support and prognostic factors of hospitalised patient with HIV (PIP) study. Chest 2000; 117: 1017–1022.
- Finch R, Schurmann D, Collins 0, Kubin R et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with com-munity-acquired pneumonia requiring initial parenteral treat-ment. Antimicrob Agents Chemother 2002; 46 (6): 1746–1754.
- Lopez-Palomo C, Martin-Zamorano M. et al. Pneumonia in HIV infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination J Med Virol 2004; 72: 517–524.
- Niederman MS. Challenges in the management of com-munity-acquired pneumonia: the role of quinolones and moxi-floxacin. Clin Infect Dis 2005; 41:S158–S166.
- Ball P, Stahlmann R, Kubin R, Choudhri S, Owens R. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther 2004; 26 (7): 940–50.